Guideline for Management of Mixed Plasmodium vivax and Plasmodium falciparum Malaria
First‑Line Artemisinin‑Based Combination Therapy for Uncomplicated Mixed Infection
Management of Severe or Complicated Mixed Infection
Radical Cure of P. vivax Hypnozoites
Geographic Considerations
Common Treatment Pitfalls to Avoid
All facts are derived from cited clinical evidence (Clinical Microbiology and Infection, 2024) and reflect current WHO and relevant national guideline recommendations.
Management of Mixed Vivax and Falciparum Malaria
Treatment Approach
- The World Health Organization recommends treating mixed P. vivax and P. falciparum infections with an artemisinin-based combination therapy (ACT) followed by primaquine (or tafenoquine) to eliminate both blood-stage parasites and P. vivax liver hypnozoites 5, 6
Treatment Algorithm
- For uncomplicated mixed infection, the American Society of Tropical Medicine and Hygiene recommends using oral ACT as first-line treatment, with preferred options including artemether-lumefantrine and dihydroartemisinin-piperaquine 5, 7
- For severe malaria, the Infectious Diseases Society of America recommends admitting to ICU and initiating intravenous artesunate, then transitioning to oral ACT after 3 doses of artesunate when parasitemia <1% 5, 8
Anti-Relapse Therapy
- The Centers for Disease Control and Prevention recommends G6PD testing before primaquine administration to prevent life-threatening hemolysis, and starting primaquine 30 mg base daily for 14 days concomitantly with ACT for G6PD-normal patients 5, 8, 9
Monitoring Protocol
- The World Health Organization recommends monitoring parasitemia every 12 hours until decline to <1%, then every 24 hours until negative, and checking laboratory tests daily, including complete blood count, hepatic, renal, and metabolic panels 5